| 引用本文：关轶茹, 相维, 张方.澳大利亚救生药物计划及对我国罕见病医疗救助制度的启示[J].中国卫生政策研究,2015,8(8):51-55 |
|
| 澳大利亚救生药物计划及对我国罕见病医疗救助制度的启示 |
| 投稿时间：2015-06-02 修订日期：2015-07-15 PDF全文浏览 HTML全文浏览 |
| 关轶茹, 相维, 张方 |
| 沈阳药科大学工商管理学院, 辽宁沈阳 110016 |
| 摘要:目的:介绍澳大利亚救生药物计划,为完善我国罕见病医疗救助制度提供参考。方法:根据文献分析澳大利亚救生药物计划的主要内容和特点,并与国内罕见病医疗救助现状进行比较。结果:澳大利亚通过孤儿药资格认证和成本效益评估将符合条件的孤儿药纳入救生药物计划,并通过财政资助为罕见病患者提供免费的治疗药物。该计划规定了严格的孤儿药和患者纳入条件,建立了罕见病临床指南和专家咨询制度,并定期开展上市后再审查,提高了孤儿药的可及性。结论:我国应当借鉴澳大利亚经验,由国家主导罕见病和孤儿药的管理,在大病医疗保险的基础上探索符合我国国情的罕见病医疗救助制度。 |
| 关键词:救生药物计划 罕见病 孤儿药 医疗保障 |
|
| The Australian Life Saving Drugs Program and its implications for medical assistance system for the rare diseases in China |
| GUAN Yi-ru, XIANG Wei, ZHANG Fang |
| Business Administration College, Shenyang Pharmaceutical University, Shenyang Liaoning 110016, China |
| Abstract:Objective: To introduce the Australian Life Saving Drugs Program (LSDP) and provide references for medical assistance system for the rare diseases in China. Methods: The main content and characteristics of LSDP were analyzed and compared with the Chinese status quo valuation. Results: Through the orphan drug designation and cost-effectiveness evaluation, eligible drugs are included in LSDP and funded to the rare disease patients. LSDP stipulated the strict funding criteria and conditions, established the Guidelines and Disease Advisory Committees, and processed the post-market reviews program in order to guarantee the medication requirements of the patients. Conclusions: The Australian experience is worth learning and China should implement a country-led management system for the rare disease and orphan drugs, and explore a medical assisstance system in line with the Chinese national condition based on the catastrophic medical insurances. |
| Key words:Australian Life Saving Drugs Program Rare disease Orphan drug Medical security |
| 摘要点击次数: 3437 全文下载次数: 2233 |
|
|
|
|
|
